BiotechTube

EO-3021 + Ramucirumab (CYRAMZA®) + Dostarlimab

Phase 1Terminated
0 watching 0 views this week💤 Quiet
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Stomach Neoplasm

Conditions

Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Neoplasms by Site, Neoplasms

Trial Timeline

Aug 10, 2023 → Jun 2, 2025

NCT ID
NCT05980416

About EO-3021 + Ramucirumab (CYRAMZA®) + Dostarlimab

EO-3021 + Ramucirumab (CYRAMZA®) + Dostarlimab is a phase 1 stage product being developed by CSPC Pharmaceutical Group Limited for Stomach Neoplasm. The current trial status is terminated. This product is registered under clinical trial identifier NCT05980416. Target conditions include Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm.

Hype Score Breakdown

Clinical
10
Activity
5
Company
9
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05980416Phase 1Terminated

Competing Products

20 competing products in Stomach Neoplasm

See all competitors
ProductCompanyStageHype Score
E0671 + rabeprazole sodium + E0671 placeboEisaiApproved
85
ParietEisaiPre-clinical
23
Ramucirumab + Placebo + Oxaliplatin + Leucovorin + 5-FluorouracilEli LillyPhase 2
52
Ramucirumab + Capecitabine + Cisplatin + S-1 + OxaliplatinEli LillyPhase 1
33
Ramucirumab + PaclitaxelEli LillyPhase 2
52
epoetin alfaJohnson & JohnsonPhase 3
77
MK0782MerckPhase 2
52
Pembrolizumab + Cisplatin + 5-fluorouracil + oxaliplatin + capecitabine + Placebo for PembrolizumabMerckPhase 3
77
Avelumab + Oxaliplatin + 5-Fluorouracil + Leucovorin + Capecitabine + Oxaliplatin + 5-Fluorouracil + Leucovorin + CapecitabineMerckPhase 3
77
Pembrolizumab + Cisplatin + 5-fluorouracil + Oxaliplatin + Capecitabine + Placebo for PembrolizumabMerckPhase 3
77
AUY922 + BYL719NovartisPhase 1
33
ECC + FOLFIRIRochePhase 3
77
Capecitabine + OxaliplatinRochePhase 3
77
Atezolizumab + Capecitabine + Oxaliplatin + DocetaxelRochePhase 2
52
Atezolizumab + Tiragolumab + Oxaliplatin + CapecitabineRochePhase 2
52
Epirubicin, Cisplatin, Capecitabine, Panitumumab + Epirubicin, Cisplatin, CapecitabineAmgenPhase 2
51
AMG 337AmgenPhase 1/2
40
AMG 337AmgenPhase 2
51
Cisplatin + S-1 + SunitinibPfizerPhase 1
32
axitinib + capecitabine + cisplatinPfizerPhase 1
32

Other Products from CSPC Pharmaceutical Group Limited

Butylphthalide + Butylphthalide placeboPhase 3
76
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenPhase 2
51
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsPhase 2
51
Sintilimab + Nab paclitaxel + CisplatinPhase 2
51
pegylated liposomal doxorubicin (PLD) + PD-1Phase 2
51